Regulation of re-replication in mammalian cells
Regulation of re-replication in mammalian cells
批准号:
10387262
负责人:
TAREK A. ABBAS
金额:
$15.9万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-03-01 至 2024-12-31
关键词:
Cell CycleCellsCharacteristicsChromatinDNADNA Double Strand BreakDNA RepairDNA biosynthesisDevelopmentDouble Strand Break RepairEnsureEnzymesEpigenetic ProcessEukaryotaExhibitsG1 PhaseGene SilencingGenerationsGenesGenomeGenomic InstabilityGenomic SegmentGenomicsGoalsHistonesLeadLicensingMalignant - descriptorMalignant NeoplasmsMammalian CellMethyltransferaseModelingMolecularNatureNuclearPlayProcessProteinsRegulationReplication InitiationReplication OriginRoleS PhaseSiteStochastic ProcessesTestinganti-cancer therapeuticcancer cellcell typecytotoxicdesigngene repressionhistone methyltransferaseinnovationwhole genome
中文摘要
项目摘要
哺乳动物细胞进化出多种不重叠的机制,以确保DNA复制启动
在每个分裂周期中只有一次复制的起源;失去对这些机制的控制
导致基因组不稳定,这是恶性转化的重要驱动因素。越来越多的证据表明
高等真核生物的起源、利用和激活受到表观遗传因素的影响,但确切的机制
在很大程度上是不确定的。我们的长期目标是阐明控制复制的基础机制
在哺乳动物细胞中的启动并理解这些机制的扰动如何引发基因组
不稳定。组蛋白甲基转移酶Set8正在成为复制启动的关键调节因子
哺乳动物细胞通过其对组蛋白H4K20的单甲基转移酶活性。细胞周期调节酶
在细胞周期的G1期对起源许可是必不可少的,但在S期被蛋白质降解;阻断
这一步骤触发了相同细胞周期内的重复复制启动或再复制。集8和
然而,H4K20me也参与转录抑制和DNA双链断裂的修复
(DSB),但这些看似独立的活动是否在复制启动或重新复制中发挥作用
不知道。最重要的是,人们对重新复制的性质或特征知之甚少
在有缺陷的Set8降解的单元中积累的产品,也没有关于
发生基因组重新复制,或者如果存在更容易重新复制的某些基因组区域
归纳法。我们的新结果表明,由有缺陷的Set8降解引起的再复制不是随机的
具有较少基因组位置的过程显示出大量且显著的拷贝数增加,这让人联想到基因组
在癌细胞中看到的放大。其他初步研究表明,重新复制可能会
起源于DNA双链断裂(DSB),它可能在复制过程中自发出现,需要
参与转录沉默和DSB修复的基因的活性。我们创新的初步方案
研究和实验方法旨在彻底检查这种替代的重复复制模式
归纳法。目的1我们将确定Re基因的大小(拷贝数增益)和基因组分布。
在有缺陷的Set8降解的细胞中复制DNA,并在DSB诱导之后。我们还将测试是否
这些参数在不同的癌细胞类型以及癌症和非癌症细胞中是不同的。目标2将决定
异常稳定的Set8和甲基化的H4K20在Set8缺陷细胞中的染色质占有率
降解,以及这些区域是否与重新复制的DNA区域重叠。目标3将定义
转录抑制和DSB修复蛋白在再复制诱导中的作用。成功地执行了
提出的AIMS有望增加我们对
并有助于更好地理解这些机制的扰动是如何引发
基因组不稳定。
英文摘要
Project Summary
Mammalian cells have evolved multiple non-overlapping mechanisms to ensure that DNA replication initiates
from origins of replications once and only once in each division cycle; loss of control over these mechanisms
induces genomic instability, an important driver of malignant transformation. Increasing evidence suggests that
origin utilization and activation in higher eukaryotes is influenced by epigenetic factors, but exact mechanisms
are largely undefined. Our long-term goals are to elucidate the underpinning mechanisms that control replication
initiation in mammalian cells and to understand how perturbations of these mechanisms provokes genomic
instability. The histone methyltransferase SET8 is emerging as a key regulator of replication initiation in
mammalian cells through its mono-methyltransferase activity on histone H4K20. The cell cycle regulated enzyme
is essential for origin licensing in G1 phase of the cell cycle, but is proteolytically degraded in S-phase; blocking
this step triggers reiterative replication initiation within the same cell cycle or re-replication. Both SET8 and
H4K20me, however, are also involved in transcriptional repression and in the repair of DNA double strand breaks
(DSBs), but whether these seemingly independent activities play a role in replication initiation or re-replication is
not known. Most importantly, little to nothing is known about the nature or characteristics of the re-replication
products that accumulate in cells with defective SET8 degradation, nor is there information on where in the
genome re-replication occurs or if there are certain genomic regions that are more prone to re-replication
induction. Our new results show that re-replication resulting from defective SET8 degradation is not a stochastic
process with few genomic sites exhibit large and significant copy number gains, reminiscent of genomic
amplifications that are seen in cancer cells. Additional preliminary studies suggest that re-replication may
originate from DNA double strand breaks (DSBs) that may spontaneously arise during replication, and requires
the activity of genes involved both in transcriptional silencing and in DSB repair. Our innovative preliminary
studies and experimental approaches are designed to thoroughly examine this alternative model of re-replication
induction. Aim 1 we will determine the magnitude (copy number gains) and genomic distribution of the re-
replicated DNA in cells with defective SET8 degradation and following the induction of DSBs. We will also test if
these parameters vary in different cancer cell types and in cancer vs. non-cancer cells. Aim 2 will determine the
chromatin occupancy of aberrantly stabilized SET8 and methylated H4K20 in cells with defective SET8
degradation, and whether these overlap with regions of re-replicated DNA. Aim 3 will define the role of
transcriptional repression and DSB repair proteins in re-replication induction. The successful execution of the
proposed aims promises to increase our understanding of the mechanisms regulating replication initiation in
mammalian cells, and lead to a better understanding of how perturbations of these mechanisms provokes
genomic instability.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of re-replication in mammalian cells
-
批准号:10320029
-
项目类别:
-
资助金额:$31.45万
-
财政年份:2020
-
负责人:TAREK A. ABBAS
-
依托单位:
Abbas Equipment Supplement
-
批准号:10799093
-
项目类别:
-
资助金额:$8.34万
-
财政年份:2020
-
负责人:TAREK A. ABBAS
-
依托单位:
Regulation of re-replication in mammalian cells
-
批准号:10539351
-
项目类别:
-
资助金额:$31.45万
-
财政年份:2020
-
负责人:TAREK A. ABBAS
-
依托单位:
The Role of CRL4-Cdt2 E3 Ubiquitin Ligase in Genomic Stability and Cancer
-
批准号:7895195
-
项目类别:
-
资助金额:$12.16万
-
财政年份:2010
-
负责人:TAREK A. ABBAS
-
依托单位:
The Role of CRL4-Cdt2 E3 Ubiquitin Ligase in Genomic Stability and Cancer
-
批准号:8066396
-
项目类别:
-
资助金额:$12.43万
-
财政年份:2010
-
负责人:TAREK A. ABBAS
-
依托单位:
The Role of CRL4-Cdt2 E3 Ubiquitin Ligase in Genomic Stability and Cancer
-
批准号:8525706
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2010
-
负责人:TAREK A. ABBAS
-
依托单位:
The Role of CRL4-Cdt2 E3 Ubiquitin Ligase in Genomic Stability and Cancer
-
批准号:8545701
-
项目类别:
-
资助金额:$23.41万
-
财政年份:2010
-
负责人:TAREK A. ABBAS
-
依托单位:
The Role of CRL4-Cdt2 E3 Ubiquitin Ligase in Genomic Stability and Cancer
-
批准号:8721855
-
项目类别:
-
资助金额:$24.15万
-
财政年份:2010
-
负责人:TAREK A. ABBAS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
分化肌细胞脱细胞ECM-cells sheet 3D
支架构建及其促进容积性肌组织缺损再
生修复应用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:肖将尉
-
依托单位:
库否细胞(Kupffer cells)受体PirB/LILRB2在非酒精性脂肪性肝炎中的作用及机制研究
-
批准号:82470907
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2024
-
负责人:余学锋
-
依托单位:
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
-
批准号:82072862
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2020
-
负责人:徐云升
-
依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
-
批准号:82070825
-
项目类别:面上项目
-
资助金额:53.0万元
-
批准年份:2020
-
负责人:徐西振
-
依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
-
批准号:81903002
-
项目类别:青年科学基金项目
-
资助金额:20.5万元
-
批准年份:2019
-
负责人:王斐斐
-
依托单位:
HA/CD44在乳腺癌转移“先导细胞”(leader cells)侵袭中的作用及机制研究
-
批准号:81402419
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2014
-
负责人:杨翠霞
-
依托单位:
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
-
批准号:81271563
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2012
-
负责人:陈正光
-
依托单位:
树突状细胞(Dendritic cells,DCs)介导的黏膜免疫对猪轮状病毒(PRV)感染的分子作用机制研究
-
批准号:31272541
-
项目类别:面上项目
-
资助金额:82.0万元
-
批准年份:2012
-
负责人:王春凤
-
依托单位:
MTA2在睾丸支持细胞(Sertoli cells)中的功能和机制研究
-
批准号:31271248
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2012
-
负责人:李伟
-
依托单位:
无外源性基因iPS cells向肠细胞分化及对肠损伤的修复
-
批准号:81160050
-
项目类别:地区科学基金项目
-
资助金额:49.0万元
-
批准年份:2011
-
负责人:邵立健
-
依托单位: